Cargando…
Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial
BACKGROUND: The newly discovered coronavirus has turned into coronavirus disease 2019 (COVID-19) pandemic and it rages at an unprecedented rate. Considering the findings of previous studies on the use of Intravenous Immunoglobulin (IVIg) for treating severe H(1)N(1) infection and the satisfying resu...
Autores principales: | Tabarsi, Payam, Barati, Saghar, Jamaati, Hamidreza, Haseli, Sara, Marjani, Majid, Moniri, Afshin, Abtahian, Zahra, Dastan, Alireza, Yousefian, Sahar, Eskandari, Raha, Saffaei, Ali, Monjazebi, Fatemeh, Vahedi, Abdolbaset, Dastan, Farzaneh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665876/ https://www.ncbi.nlm.nih.gov/pubmed/33214093 http://dx.doi.org/10.1016/j.intimp.2020.107205 |
Ejemplares similares
-
No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial
por: Jamaati, Hamidreza, et al.
Publicado: (2021) -
The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2023) -
Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial
por: Barati, Saghar, et al.
Publicado: (2021) -
Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis
por: Yousefian, Sahar, et al.
Publicado: (2021) -
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial
por: Dastan, Farzaneh, et al.
Publicado: (2020)